Get started
Author

Gabriele Buda

Observed names: BUDA, GABRIELE, Buda G, Buda, Gabriele, G B Gabriele Buda, G Buda, G. Buda, gabriele buda
Observed institutions: University of Pisa, University of Messina, Inserm, Scuola Superiore Sant'Anna, Universidad de Granada, German Cancer Research Center, University of Ferrara, Ospedale Santa Chiara, Copernicus Memorial Hospital, Medical University of Lodz, Centre de Recherche en Cancérologie de Lyon, Pfizer-University of Granada-Junta de Andalucía Centre for Genomics and Oncological Research, Fondazione Toscana Gabriele Monasterio, Azienda Ospedaliera Universitaria Pisana, Azienda USL Toscana Nord Ovest, University College London, Universitat de Barcelona
ORCID: 0000-0002-5240-5611
Observed ORCID: 0000-0002-5240-5611
OpenAlex ID: A5011287280
Unexpected cardiotoxicity in haematological bortezomib treated patients
2007 · Enrico Orciuolo, Gabriele Buda, et al. · British Journal of Haematology · 185
PDF
[18F]-Florbetaben PET/CT for Differential Diagnosis Among Cardiac Immunoglobulin Light Chain, Transthyretin Amyloidosis, and Mimicking Conditions
2020 · Dario Genovesi, Giuseppe Vergaro, et al. · JACC. Cardiovascular imaging · 126
PDF
Characteristics and outcome of therapy‐related myeloid neoplasms: Report from the I talian network on secondary leukemias
2015 · Luana Fianchi, Livio Pagano, et al. · American Journal of Hematology · 123
PDF
Keys to early diagnosis of cardiac amyloidosis: red flags from clinical, laboratory and imaging findings
2019 · Giuseppe Vergaro, Alberto Aimo, et al. · European Journal of Preventive Cardiology · 116
Secondary malignancies after treatment for indolent non-Hodgkin's lymphoma: a 16-year follow-up study
2008 · S. Sacchi, L. Marcheselli, et al. · Haematologica · 106
PDF
Atrial amyloidosis: mechanisms and clinical manifestations
2022 · Giuseppe Vergaro, Alberto Aimo, et al. · European Journal of Heart Failure · 92
PDF
Piezoelectric Signals in Vascularized Bone Regeneration
2021 · Delfo D’Alessandro, Claudio Ricci, et al. · Biomolecules · 65
PDF
N-Terminal Pro-B-Type Natriuretic Peptide and High-Sensitivity Troponin T Hold Diagnostic Value in Cardiac Amyloidosis
2023 · Giuseppe Vergaro, Vincenzo Castiglione, et al. · European Journal of Heart Failure · 63
PDF
Polymorphisms in the multiple drug resistance protein 1 and in P-glycoprotein 1 are associated with time to event outcomes in patients with advanced multiple myeloma treated with bortezomib and pegylated liposomal doxorubicin
2010 · Gabriele Buda, Deborah Ricci, et al. · Annals of Hematology · 61
PDF
High-dose zinc oral supplementation after stem cell transplantation causes an increase of TRECs and CD4+ naïve lymphocytes and prevents TTV reactivation
2018 · Lorenzo Iovino, Francesco Mazziotta, et al. · Leukemia Research · 52
Exome sequencing identifies germline variants in DIS3 in familial multiple myeloma
2019 · Maroulio Pertesi, Maxime Vallée, et al. · Leukemia · 48
Tumor dormancy as an alternative step in the development of chemoresistance and metastasis - clinical implications
2019 · Federico Rossari, Cristina Zucchinetti, et al. · Cellular Oncology · 47
Therapies for cardiac light chain amyloidosis: An update
2018 · Alberto Aimo, Gabriele Buda, et al. · International Journal of Cardiology · 44
PDF
MDR1 polymorphism influences the outcome of multiple myeloma patients
2007 · Gabriele Buda, Valentina Maggini, et al. · British Journal of Haematology · 44
Genome-wide association study identifies variants at 16p13 associated with survival in multiple myeloma patients
2015 · Elad Ziv, Eric Dean, et al. · Nature Communications · 43
PDF
Human autologous plasma‐derived clot as a biological scaffold for mesenchymal stem cells in treatment of orthopedic healing
2007 · Luisa Trombi, Letizia Mattii, et al. · Journal of Orthopaedic Research® · 42
PDF
Wild-type transthyretin cardiac amyloidosis is not rare in elderly subjects: the CATCH screening study
2024 · Alberto Aimo, Giuseppe Vergaro, et al. · European Journal of Preventive Cardiology · 41
PDF
The CoV-2 outbreak: how hematologists could help to fight Covid-19
2020 · Sara Galimberti, Chiara Baldini, et al. · Pharmacological Research · 41
Risk of multiple myeloma is associated with polymorphisms within telomerase genes and telomere length
2014 · Daniele Campa, Alessandro Martino, et al. · International Journal of Cancer · 40
Significant efficacy of 2-CdA with or without rituximab in the treatment of splenic marginal zone lymphoma (SMZL)
2009 · G. Cervetti, S. Galimberti, et al. · Annals of Oncology · 38
PDF
A real‐world efficacy and safety analysis of combined carfilzomib, lenalidomide, and dexamethasone (KRd) in relapsed/refractory multiple myeloma
2020 · Serena Rocchi, Paola Tacchetti, et al. · Hematological Oncology · 35
2CdA chemotherapy and rituximab in the treatment of marginal zone lymphoma
2009 · Enrico Orciuolo, Gabriele Buda, et al. · Leukemia Research · 33
MDR1 diplotypes as prognostic markers in multiple myeloma
2008 · Valentina Maggini, Gabriele Buda, et al. · Pharmacogenetics and Genomics · 30
A randomized trial with melphalan and prednisone versus melphalan and prednisone plus thalidomide in newly diagnosed multiple myeloma patients not eligible for autologous stem cell transplant
2011 · Stefano Sacchi, Raffaella Marcheselli, et al. · Leukemia & lymphoma/Leukemia and lymphoma · 28
CD45 expression in low-grade B-cell non-Hodgkin's lymphomas
2007 · Giovanni Carulli, Elisa Cannizzo, et al. · Leukemia Research · 28
Works count: 276
Citation count: 2,560
H-index: 26
I10-index: 67
Year
Topic
Type